ArticleScientific reports2019
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Knowledge map of recurrence in tenosynovial giant cell tumor: a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- Total knee arthroplasty in pigmented villonodular synovitis osteoarthritis: a systematic review of literature.Musculoskeletal surgery · 2024Pooled it
- Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2020Pooled it
- Trial
- CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet (London, England) · 2024Trial
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
- Expression of Molecular Markers Associated with Tenosynovial Giant Cell Tumours and Bone Destruction: A Systematic Review.Journal of clinical medicine · 2026Review
- TGCT of the shoulder - a case series and literature review.Archives of orthopaedic and trauma surgery · 2026Review
- Bilateral Localized-Tenosynovial Giant Cell Tumor of the Knee: Case Report and Review.Journal of clinical medicine · 2026Article
- Medical Management of Tenosynovial Giant Cell Tumor.Current oncology reports · 2025Review
- Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.Future oncology (London, England) · 2025Observational
- Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update.Medicina (Kaunas, Lithuania) · 2024Review
- Recurrence-Free Survival after Synovectomy and Subsequent Radiosynoviorthesis in Patients with Synovitis of the Knee-A Retrospective Data Analysis.Journal of clinical medicine · 2024Article
- Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.Future oncology (London, England) · 2024Observational
- Tenosynovial giant cell tumor: a case report.Journal of medical case reports · 2023Article
- Diffuse-type tenosynovial giant cell tumor between the suboccipital bone and posterior C1 arch: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Article
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.Journal of surgical oncology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 11 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.